1.
World J Clin Oncol
; 13(9): 758-761, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36212602
RESUMO
Recent data from a phase 3 trial have shown that the addition of immunotherapy to neoadjuvant chemotherapy improves event-free survival in patients with non-small-cell lung cancer (NSCLC). This is the first positive phase 3 trial in this setting, although several phase 3 trials are currently investigating the efficacy of neoadjuvant and adjuvant immunotherapy in resectable NSCLC.